2024 Critical Care Congress Skip to main content
2024 Critical Care Congress Main banner
Back
ViewAttendees 44

Infection
90-Minute Session

Clinical Evidence for Host-Directed Therapeutics

Sunday, January 21, 2024
11:45 AM – 1:15 PM MT
Location: North-120A
CE: 1.5

This session will consist of a discussion of the potential opportunity for host-directed therapeutics (HDTs) for treating infectious diseases and impacting critical care medicine. Opportunities and challenges related to the development and repurposing of HDTs will be explored.

Congress features sessions on a record-breaking number of new journal articles, guidelines, and research from SCCM and other leading medical journals. Find details here.

Learning Objectives:

  • Raise awareness of the potential opportunity for clinical development of host-directed therapeutics (HDTs)
  • Illuminate the strategic value of HDTs in pandemic preparedness
  • Elaborate on potential opportunities to repurpose therapeutics
  • Explore the clinical evidence needed to support further development and use of repurposed therapeutics

Presentations:

  • Repurposing Host-Directed Therapeutics for COVID-19
  • The Role of Platform Trials
  • The Use of Clinical Data to Inform and Identify the Potential New Value of Existing HDTs
  • Clinical Evidence Necessary to Support Clinical Guidelines for the Use of HDTs
  • Clinical Unmet Need for HDTs
  • BARDA’s Interest in HDTs and Funding Opportunities
  • Panel Discussion